首页> 外国专利> Purine receptor inhibition as a therapeutic strategy in spinal cord and brain

Purine receptor inhibition as a therapeutic strategy in spinal cord and brain

机译:嘌呤受体抑制作为脊髓和大脑的治疗策略

摘要

The present invention is directed to a method of treating a subject with acute spinal cord injury by administering a purine receptor antagonist to the subject under conditions effective to treat spinal cord injury. The purine receptor antagonist inhibits P2X purine receptor activation. The inhibition of P2X purine receptor activation can also be used in conjunction with methods of treating a subject with spinal cord ischemia resulting from stroke or vascular insult, interruption, or mechanical injury, treating a subject with ischemic or traumatic insults of brain tissue in regions expressing P2X receptors, and for inhibiting ATP-triggered brain or spinal cord cell death.
机译:本发明涉及通过在有效治疗脊髓损伤的条件下向患者施用嘌呤受体拮抗剂来治疗患有急性脊髓损伤的对象的方法。嘌呤受体拮抗剂抑制P2X嘌呤受体激活。 P2X嘌呤受体激活的抑制也可以与以下方法结合使用:治疗由中风或血管损伤,中断或机械损伤引起的脊髓缺血的受试者,在表达区域的脑组织的缺血或创伤性损伤治疗受试者的方法P2X受体,用于抑制ATP触发的脑或脊髓细胞死亡。

著录项

  • 公开/公告号US2005164975A1

    专利类型

  • 公开/公告日2005-07-28

    原文格式PDF

  • 申请/专利权人 MAIKEN NEDERGAARD;STEVEN A. GOLDMAN;

    申请/专利号US20040979526

  • 发明设计人 STEVEN A. GOLDMAN;MAIKEN NEDERGAARD;

    申请日2004-11-02

  • 分类号A61K31/655;A61K31/4965;A61K31/496;A61K31/7076;

  • 国家 US

  • 入库时间 2022-08-21 22:23:14

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号